Anika Therapeutics reported $0 in Loan Capital for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Loan Capital Change
Acceleron Pharma XLRN:US $ 0M 0M
Agenus AGEN:US $ 18.95M 0.03M
Agios Pharmaceuticals AGIO:US $ 0.17M 0.08M
Anika Therapeutics ANIK:US $ 0M 0M
Arrowhead Research ARWR:US $ 0 0
Chemocentryx CCXI:US $ 11.57M 3.3M
Dicerna Pharmaceuticals DRNA:US $ 0M 0M
Flexion Therapeutics FLXN:US $ 220.02M 14.99M
Halozyme Therapeutics HALO:US $ 785.57M 0.84M
Heron Therapeutics HRTX:US $ 148.98M 148.98M
Immunogen IMGN:US $ 0M 0M
Insmed INSM:US $ 562.86M 186.87M
Karyopharm Therapeutics KPTI:US $ 301.38M 59.58M
Ligand Pharmaceuticals LGND:US $ 315.32M 36.99M
Macrogenics MGNX:US $ 0 0
Merit Medical Systems MMSI:US $ 284.9M 27.98M
Peregrine Pharmaceuticals PPHM:US $ 138.81M 41.86M
Rigel Pharmaceuticals RIGL:US $ 19.86M 0.02M
Sangamo Biosciences SGMO:US $ 0M 0M
Stryker SYK:US $ 12734M 325M
Surmodics SRDX:US $ 0M 0M
Veracyte VCYT:US $ 0.92M 0.05M
Xencor XNCR:US $ 0M 0M
Zimmer Biomet Holdings Inc ZBH:US $ 6.8B 736.2M